Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $34.2500 (1.62%) ($34.2500 - $34.2500) on Tue. May. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.5% (three month average) | RSI | 21 | Latest Price | $34.2500(1.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2% a day on average for past five trading days. | Weekly Trend | TGTX declines -10.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) IWO(59%) ARKK(58%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.75% in a week (0% probabilities). VIXM(-42%) VXX(-36%) UUP(-18%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.75% (StdDev 3.5%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $20.13(-41.23%) | Resistance Level | $39.7 | 5 Day Moving Average | $34.69(-1.27%) | 10 Day Moving Average | $36.88(-7.13%) | 20 Day Moving Average | $39.7(-13.73%) | To recent high | -32% | To recent low | 1.6% | Market Cap | $4.338b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |